• NEWS
    • Cover Features
    • Latest News
    • Job Movements
    • Startup Marvels
    • Good Deeds – CSR
    • Workplace Cultures
  • BRANDS
    • Campaigns
    • Spotlight
  • LEADERSHIP
    • Global Leaders
    • Incredible Journeys
    • The Founder
    • PRO Speak
  • INDUSTRY
    • Education
    • Modern Healthcare
    • Travel & Tourism
  • FEATURES
    • Life
    • B&L Dialogue
    • Videos Series
  • About Us
    • Brands and Leaders INDIA
    • Advertise with us
    • Privacy Policy
    • Contact Us
  • NEWS
    • Cover Features
    • Latest News
    • Job Movements
    • Startup Marvels
    • Good Deeds – CSR
    • Workplace Cultures
  • BRANDS
    • Campaigns
    • Spotlight
  • LEADERSHIP
    • Global Leaders
    • Incredible Journeys
    • The Founder
    • PRO Speak
  • INDUSTRY
    • Education
    • Modern Healthcare
    • Travel & Tourism
  • FEATURES
    • Life
    • B&L Dialogue
    • Videos Series
  • About Us
    • Brands and Leaders INDIA
    • Advertise with us
    • Privacy Policy
    • Contact Us
Home » Modern Healthcare

GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations

B&L Editorial Posted On May 30, 2020
0
106 Views
2


0
Shares
  • Share On Facebook
  • Tweet It

GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19. As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people. Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections.

GSK has prioritised its efforts towards making its pandemic adjuvant technology available to partners developing promising COVID-19 vaccine candidates that are suitable for use with an adjuvant. To date, the company has formed several collaborations, including with scientific partners in North America, Europe and China, to develop vaccines. Discussions with potential partners on further
collaborations are ongoing.

(Picture Credits : RawPixel.com)

Confirmation of the enhanced manufacturing capacity follows completion of a review conducted across the company’s global supply network. GSK will manufacture, fill and finish adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe. Roger Connor, President, GSK Global Vaccines, said: “We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so.

We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple COVID-19 vaccines. With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19.”

Given the unprecedented need to develop COVID-19 vaccines, GSK has started manufacture of the adjuvant at risk. The company is in discussions with Governments and global institutions about funding for production and supply of the adjuvant. GSK is committed to making its adjuvant available through mechanisms that offer fair access for people across the world. Making the adjuvant available to the world’s poorest countries will also be a key part of these efforts, including donations, by working with governments and the global institutions
that prioritise access.

Overall GSK does not expect to profit from sales of its portfolio of collaborations for COVID-19 vaccines made during this pandemic phase, as profit generated will be invested in support of coronavirus related research and long-term pandemic preparedness, either through GSK’s internal investments, or with external partners.

About GSK
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England. Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization’s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine

Post Views: 106
0
Shares
  • Share On Facebook
  • Tweet It




Consumers Turn to Used Cars Market in Hyderabad With Right Cars
Read Next

Consumers Turn to Used Cars Market in Hyderabad With Right Cars

Leave A Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • FEATURES

    • Corona Warriors Of India : Sonu Sood, Minal Dakhave...
      May 27, 2020
    • B&L DIALOGUE : MR. DINESH VYAS, Sr.Vice President Marketing,...
      May 17, 2020
    • 8 Mistakes that can kill startups
      May 13, 2020
    • Helping you avoid COVID-19 online security risks
      May 7, 2020
    • B&L DIALOGUE : MR. PANKAJ PODDAR, CEO, COSMO FILMS
      May 7, 2020

  • Like Us On Facebook

    Facebook Pagelike Widget
  • Latest News

    • Tata AIA Life Insurance Hosts Virtual Health and Wellness...
      September 2, 2020
    • Datacultr selected in Finance Forward MENA 2020
      September 2, 2020
    • Tommy Hilfiger Accelerates Sustainability Journey With...
      September 1, 2020
    • Melange by Lifestyle, Announces Deepika Padukone as Brand...
      August 12, 2020
    • Reveal Acquires NexLP to become the leading AI-powered...
      August 12, 2020


  • Home
  • Brands and Leaders INDIA
  • TV Series
  • Advertise with us
  • Contact Us
© Copyright BRANDS & LEADERS 2020
Press enter/return to begin your search